

Jian Sun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/153084/publications.pdf>

Version: 2024-02-01

88
papers

3,381
citations

172457

29
h-index

161849

54
g-index

90
all docs

90
docs citations

90
times ranked

4604
citing authors

#	ARTICLE	IF	CITATIONS
1	Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. <i>Nature Medicine</i> , 2020, 26, 1193-1195.	30.7	352
2	Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). <i>Journal of Clinical and Translational Hepatology</i> , 2017, 5, 297-318.	1.4	181
3	Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. <i>Hepatology</i> , 2001, 34, 1027-1034.	7.3	171
4	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2020, 73, 1368-1378.	3.7	158
5	Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies. <i>Journal of Medical Virology</i> , 2003, 71, 360-366.	5.0	152
6	Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection. <i>Hepatology</i> , 2019, 69, 1816-1827.	7.3	132
7	qFibrosis: A fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2014, 61, 260-269.	3.7	127
8	Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 545-553.	2.8	113
9	Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. <i>Gut</i> , 2016, 65, 313-320.	12.1	112
10	Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. <i>Journal of Hepatology</i> , 2005, 42, 813-819.	3.7	95
11	High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. <i>Journal of Hepatology</i> , 2012, 56, 775-781.	3.7	92
12	Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 97-104.	8.1	80
13	Circulating chemokine (C-X-C Motif) receptor 5 ⁺ CD4 ⁺ T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection. <i>Hepatology</i> , 2013, 58, 1277-1286.	7.3	78
14	Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucleos(t)ide Analogue Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 719-727.e7.	4.4	72
15	The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: A randomized, controlled study. <i>Hepatology</i> , 2014, 59, 1283-1292.	7.3	69
16	Effectiveness of Prophylactic Anti-HBV Therapy in Allogeneic Hematopoietic Stem Cell Transplantation with HBsAg Positive Donors. <i>American Journal of Transplantation</i> , 2005, 5, 1437-1445.	4.7	62
17	CXCL13-mediated recruitment of intrahepatic CXCR5 ⁺ CD8 ⁺ T cells favors viral control in chronic HBV infection. <i>Journal of Hepatology</i> , 2020, 72, 420-430.	3.7	62
18	Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature Mutation in Treated Chronic Hepatitis B Patients. <i>Hepatology</i> , 2021, 73, 41-52.	7.3	57

#	ARTICLE	IF	CITATIONS
19	Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 457-467.e21.	4.4	56
20	Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 182-191.e1.	4.4	53
21	Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study. <i>Journal of Infectious Diseases</i> , 2017, 215, 581-589.	4.0	52
22	Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2020, 222, 611-618.	4.0	50
23	A novel hepatitis B virus genotyping system by using restriction fragment length polymorphism patterns of S gene amplicons. <i>World Journal of Gastroenterology</i> , 2004, 10, 3132.	3.3	45
24	Interleukin-21 is upregulated in hepatitis B-related acute-on-chronic liver failure and associated with severity of liver disease. <i>Journal of Viral Hepatitis</i> , 2011, 18, 458-467.	2.0	44
25	Restored Circulating Invariant NKT Cells Are Associated with Viral Control in Patients with Chronic Hepatitis B. <i>PLoS ONE</i> , 2011, 6, e28871.	2.5	39
26	Hepatitis B virus genotype B with G1896A and A1762T/G1764A mutations is associated with hepatitis B related acute-on-chronic liver failure. <i>Journal of Medical Virology</i> , 2011, 83, 1544-1550.	5.0	37
27	Management of chronic hepatitis B: experience from China. <i>Journal of Viral Hepatitis</i> , 2010, 17, 10-17.	2.0	36
28	Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study. <i>Journal of Hepatology</i> , 2016, 65, 674-682.	3.7	36
29	Interpretation of liver stiffness measurement-based approach for the monitoring of hepatitis B patients with antiviral therapy: A 2-year prospective study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 296-305.	2.0	35
30	Single-cell RNA sequencing reveals the sustained immune cell dysfunction in the pathogenesis of sepsis secondary to bacterial pneumonia. <i>Genomics</i> , 2021, 113, 1219-1233.	2.9	29
31	A cross-sectional assessment of health-related quality of life in Chinese patients with chronic hepatitis c virus infection with EQ-5D. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 124.	2.4	28
32	Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: A single center experience. <i>Journal of Medical Virology</i> , 2005, 75, 391-398.	5.0	27
33	Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy. <i>Gut</i> , 2020, 69, 1116-1126.	12.1	27
34	Biogenesis and molecular characteristics of serum hepatitis B virus RNA. <i>PLoS Pathogens</i> , 2020, 16, e1008945.	4.7	27
35	Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 748-755.	2.8	26
36	Lower Expression of MicroRNA-155 Contributes to Dysfunction of Natural Killer Cells in Patients with Chronic Hepatitis B. <i>Frontiers in Immunology</i> , 2017, 8, 1173.	4.8	24

#	ARTICLE	IF	CITATIONS
37	Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 692-700.	3.7	22
38	Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 197.	17.1	22
39	Association between vitamin D level and viral load or fibrosis stage in chronic hepatitis B patients from Southern China. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 566-574.	2.8	21
40	Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors. <i>Liver International</i> , 2020, 40, 2316-2325.	3.9	21
41	Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 424-431.	3.7	20
42	Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2018, 48, E213-E221.	3.4	19
43	Interleukin 21 Reinvigorates the Antiviral Activity of Hepatitis B Virus (HBV)-Specific CD8+ T Cells in Chronic HBV Infection. <i>Journal of Infectious Diseases</i> , 2019, 219, 750-759.	4.0	19
44	Aberrant expression and dysfunction of TLR2 and its soluble form in chronic HBV infection and its regulation by antiviral therapy. <i>Antiviral Research</i> , 2015, 118, 10-19.	4.1	18
45	Variants in STAT4 Associated With Cure of Chronic HBV Infection in HBeAg-positive Patients Treated With Pegylated Interferon-alpha. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 196-204.e8.	4.4	18
46	Cellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy. <i>Virology Journal</i> , 2011, 8, 69.	3.4	17
47	Metabolic Defects of Peripheral T Cells in COVID-19 Patients. <i>Journal of Immunology</i> , 2021, 206, 2900-2908.	0.8	17
48	Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-2a. <i>Antiviral Research</i> , 2009, 81, 88-91.	4.1	15
49	Circulating HBV RNA: From biology to clinical applications. <i>Hepatology</i> , 2022, 76, 1520-1530.	7.3	15
50	Novel Evidence of HBV Recombination in Family Cluster Infections in Western China. <i>PLoS ONE</i> , 2012, 7, e38241.	2.5	14
51	Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy. <i>Scientific Reports</i> , 2015, 5, 17123.	3.3	14
52	Naturally occurring deletions/insertions in HBV core promoter tend to decrease in HBeAg-positive chronic hepatitis B patients during antiviral therapy. <i>Antiviral Therapy</i> , 2015, 20, 623-632.	1.0	14
53	Elevated Expression of Chemokine CXCL13 in Chronic Hepatitis B Patients Links to Immune Control during Antiviral Therapy. <i>Frontiers in Immunology</i> , 2017, 8, 323.	4.8	14
54	Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 329-338.	3.7	14

#	ARTICLE	IF	CITATIONS
55	A missense variant in complement factor B (<i>CFB</i>) is a potential predictor of 24-week off-treatment response to PegIFN α therapy in Chinese HBeAg-positive chronic hepatitis B patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 469-478.	3.7	13
56	Prevention and management of drug resistant hepatitis B virus infections. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1432-1440.	2.8	12
57	Effect of hepatitis B virus subgenotype on antiviral response in nucleoside-treated hepatitis B envelope antigen-positive patients. <i>Hepatology Research</i> , 2018, 48, 134-143.	3.4	12
58	Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 709-714.	3.7	12
59	TCR β +CD4 $^+$ CD8 $^+$ T Cells Suppress the CD8+ T-Cell Response to Hepatitis B Virus Peptides, and Are Associated with Viral Control in Chronic Hepatitis B. <i>PLoS ONE</i> , 2014, 9, e88475.	2.5	12
60	Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy. <i>Journal of Infectious Diseases</i> , 2022, 226, 881-890.	4.0	12
61	Aspartate aminotransferase to platelet ratio index " a reliable predictor of therapeutic efficacy and improvement of Ishak score in chronic hepatitis B patients treated with nucleoside analogues. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, 133-142.	1.2	11
62	Prevalence of chronic kidney disease in patients with chronic hepatitis B: A cross-sectional survey. <i>Journal of Viral Hepatitis</i> , 2017, 24, 1043-1051.	2.0	11
63	Complementarity-Determining Region 3 Size Spectratypes of T Cell Receptor β Chains in CD8+T Cells following Antiviral Treatment of Chronic Hepatitis B. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 888-894.	3.2	10
64	Quantification of hepatitis B surface antigen and HBe antigen: correlation between Elecsys and Architect assays. <i>Journal of Viral Hepatitis</i> , 2013, 20, 422-429.	2.0	10
65	Methodology-dependent performance of serum HBV RNA in predicting treatment outcomes in chronic hepatitis B patients. <i>Antiviral Research</i> , 2021, 189, 105037.	4.1	10
66	The Cumulative Rate of SARS-CoV-2 Infection in Chinese Hemodialysis Patients. <i>Kidney International Reports</i> , 2020, 5, 1416-1421.	0.8	9
67	Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis. <i>Advances in Therapy</i> , 2016, 33, 519-531.	2.9	8
68	Dynamic Perturbations of CD4 and CD8 T Cell Receptor Repertoires in Chronic Hepatitis B Patients upon Oral Antiviral Therapy. <i>Frontiers in Immunology</i> , 2017, 8, 1142.	4.8	8
69	Improvements in the management of chronic hepatitis B virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 1153-1166.	3.0	8
70	Longitudinal Change of Body Mass Index Is Associated With Alanine Aminotransferase Elevation After Complete Viral Suppression in Chronic Hepatitis B Patients. <i>Journal of Infectious Diseases</i> , 2019, 220, 1469-1476.	4.0	7
71	Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of nonadvanced liver fibrosis for chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2018, 25, 598-607.	2.0	6
72	Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China. <i>BMC Gastroenterology</i> , 2019, 19, 65.	2.0	6

#	ARTICLE	IF	CITATIONS
73	Development and validation of a model for hepatitis B e antigen seroconversion in entecavir-treated patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , 2020, 92, 1206-1213.	5.0	5
74	P1067 RESPONSE-GUIDED PEGINTERFERON ALFA-2a (PegIFN alfa-2a) THERAPY IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B (CHB). <i>Journal of Hepatology</i> , 2014, 60, S432-S433.	3.7	3
75	Metabolic defects in splenic B cell compartments from patients with liver cirrhosis. <i>Cell Death and Disease</i> , 2020, 11, 915.	6.3	3
76	Small surface antigen variants of HBV associated with responses to telbivudine treatment in chronic hepatitis B patients. <i>Antiviral Therapy</i> , 2016, 22, 43-51.	1.0	2
77	Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B. <i>Journal of Hepatology</i> , 2019, 71, 1263-1264.	3.7	2
78	Editorial: serum HBV RNA biphasic decline in patients with HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 883-884.	3.7	2
79	Commentary: prognostication of chronic hepatitis B—are Fibrotest and Fibroscan the final answers?. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 1113-1113.	3.7	1
80	Combination Therapy With Tenofovir and Peginterferon May Not Be Translated Into Current Clinical Practice. <i>Gastroenterology</i> , 2016, 150, 1253-1254.	1.3	1
81	The nucleotide changes within HBV core promoter/precore during the first 12 weeks of nucleos(t)ide treatment might be associated with a better virological response. <i>Infection, Genetics and Evolution</i> , 2017, 49, 116-121.	2.3	1
82	Hepatocyte-Derived L-Carnitine Restricts Hepatitis B Surface Antigen Loss Through an Immunosuppressive Effect on Germinal Center-Related Immune Cells. <i>Journal of Infectious Diseases</i> , 2021, , .	4.0	1
83	Letter to the Editor: Probability of HBsAg loss after nucleo(s)ide analogue withdrawal depends on HBV genotype and viral antigen levels. <i>Journal of Hepatology</i> , 2022, , .	3.7	1
84	Editorial: sofosbuvir plus daclatasvir for the treatment of hepatitis C—can one size fit all?. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 853-854.	3.7	0
85	Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. <i>JAMA Oncology</i> , 2019, 5, 915.	7.1	0
86	Is the World Health Organization Hepatitis B Virus (HBV) DNA Standard Appropriate for Standardizing Serum HBV RNA Assays?. <i>Clinical Infectious Diseases</i> , 2020, 73, e2821-e2823.	5.8	0
87	REPLY:. <i>Hepatology</i> , 2021, 73, 2076-2077.	7.3	0
88	Letter to the Editor: Can the Ratio of Serum HBV RNA to DNA Reflect the Reverse-Transcription Efficiency of Viral pgRNA?. <i>Hepatology</i> , 2021, 74, 532-533.	7.3	0